Medicenna Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Conferences Trial results

10 April 2024

AACR 2024 – Medicenna looks for a cytokine renaissance

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

Subscribe to Medicenna Therapeutics